Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. by Vieira Barbosa, J. et al.
Original article | Published 04 May 2021 | doi:10.4414/smw.2021.20502
Cite this as: Swiss Med Wkly. 2021;151:w20502
Autochthonous hepatitis E as a cause of
acute-on-chronic liver failure and death:
histopathology can be misleading but
transaminases may provide a clue
Vieira Barbosa Joanaab, Müllhaupt Beatc, Brunner Felixd, Filipowicz Sinnreich Magdalenae, Semela Davidf, Montani Matteog,
Cathomas Gierih, Neuweiler Jörgi, Gouttenoire Jérômea, Artru Florenta, Louvet Alexandrej, Mathurin Philippej, Sempoux
Christinek, Lenggenhager Danielal, Weber Achiml, Moradpour Dariusa*, Fraga Montserrata*
a Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Switzerland
b Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
c Department of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland
d Hepatology, University Clinic for Visceral Surgery and Medicine, University Hospital Bern, Switzerland
e Division of Gastroenterology and Hepatology, Kantonspital Baselland Liestal, Switzerland
f Division of Gastroenterology and Hepatology, Cantonal Hospital St Gallen, Switzerland
g Institute of Pathology, University Hospital Bern, Switzerland
h Institute of Pathology, Kantonspital Baselland Liestal, Switzerland
i Institute of Pathology, Cantonal Hospital St Gallen, Switzerland
j Service Maladies de l'Appareil Digestif, Lille University Hospital and University of Lille, France
k Institute of Pathology, Lausanne University Hospital and University of Lausanne, Switzerland
l Department of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Switzerland
Summary
BACKGROUND AND AIM: Acute decompensation and
death have been observed in patients with acute hepatitis
E virus (HEV) infection and preexisting liver cirrhosis.
However, the clinical, laboratory and histological features
need to be fully characterised.
METHODS: Some of us recently described the histological
presentation of hepatitis E in a large panel of liver tissue
specimens. Here, we conducted a case-control study to
investigate the clinical and laboratory features of the sub-
set of patients with HEV-related acute-on-chronic liver fail-
ure (ACLF) and death. Each patient was matched to three
control patients with histologically confirmed severe al-
coholic hepatitis based on sex, age, total bilirubin, INR,
serum creatinine and MELD score on admission.
RESULTS: Of 5 patients who died in a context of HEV-re-
lated ACLF, 3 (60%) were male and the median age was
66 years (range 51–76). Median alanine aminotransferase
(ALT) at presentation was 2610 U/l (range 705–3134) and
aspartate aminotransferase (AST) 2818 U/l (range
1176–8611). Liver function was heavily altered in all pa-
tients. Histological analyses revealed steatohepatitis on a
background of cirrhosis, suggestive of an alcoholic or non-
alcoholic origin. Based on histopathology, alcoholic hepati-
tis was initially suspected in two patients and corticos-
teroid treatment was initiated. Ribavirin was started in four
patients. Median time from hospitalisation to death was 17
days (range 6–25 days). AST levels in patients with HEV-
related ACLF were significantly higher as compared to the
matched patients with severe alcoholic hepatitis.
CONCLUSION: Typical histopathological features of viral
hepatitis may be absent in ACLF caused by HEV infection.
HEV infection should be sought in acute decompensation
of cirrhosis and ACLF even in the absence of histological
changes suggesting viral infection.
Introduction
Hepatitis E virus (HEV) infection is one of the most com-
mon causes of acute hepatitis worldwide [1]. HEV is a pos-
itive-strand RNA virus classified in the Hepeviridae fami-
ly [2]. HEV genotypes 1 and 2 are transmitted from human
to human via the faecal-oral route in resource-limited set-
tings, mainly through contaminated drinking water. HEV
genotypes 3 and 4 represent a primarily porcine zoonosis,
causing an estimated 2 million foodborne infections per
year in Europe alone [3].
Most HEV genotype 3 infections are asymptomatic or as-
sociated with only mild and nonspecific symptoms. How-
ever, symptomatic autochthonous acute hepatitis E is ob-
served notably in middle-aged and elderly men, and some
patients present extrahepatic, particularly neurological
manifestations [1, 3]. A severe course and death have been
observed in patients with preexisting chronic liver disease,
especially in those with underlying cirrhosis [4–9; re-
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HEV infection as a cause of acute-on-chronic liver failure
(ACLF) in middle- and high-income regions, as well as
the associated clinical, laboratory and histological features,
have yet to be fully assessed.
Histopathological features of HEV infection are highly
variable and can overlap with other causes of hepatitis. A
recent study by Lenggenhager et al., performed on 52 liver
tissue specimens from 41 patients with polymerase chain-
reaction (PCR)-proven acute or chronic hepatitis E, found
that the histological features of hepatitis E are determined
by the patients’ immune status and preexisting liver con-
dition [11]. In particular, patients with decompensation of
preexisting cirrhosis showed mainly features observed in
patients with nonalcoholic and alcoholic hepatitis, raising
the question as to how patients with HEV-related ACLF
can be identified. Hence, clinical and laboratory features,
such as the presence of high transaminase levels, may pro-
vide a clue for early diagnosis of HEV infection in cirrhotic
patients. However, studies describing in detail the clinical,
laboratory and histological characteristics of these patients
together are still lacking in the literature.
On this background, we sought to examine in detail the
clinical and laboratory features of the subset of patients
who died in the context of HEV-related ACLF and to com-
pare their transaminase levels with those of patients with
histologically confirmed severe alcoholic hepatitis.
Patients and methods
Study population and design
We conducted a case-control study to compare transami-
nase levels of patients with HEV-related ACLF with those
of patients with histologically confirmed severe alcoholic
hepatitis. Swiss gastroenterologists and hepatologists were
solicited to report cases of death related to acute hepatitis
E. Only patients with HEV infection documented by PCR
for HEV RNA were included. Patients presenting only
positive anti-HEV IgM but negative PCR for HEV RNA in
plasma and/or stool were excluded. Clinical and laboratory
data were assessed retrospectively using standardised med-
ical records; the histological features have been described
recently [11]. Patients included in this study were evaluat-
ed between January 2015 and December 2018.
Controls were selected from a large prospective cohort of
398 patients with severe alcoholic hepatitis described pre-
viously [12]. Severe alcoholic hepatitis was defined by the
presence of a Maddrey’s discriminant function ≥32 in a
patient with histologically confirmed alcoholic hepatitis.
HEV infection was ruled out by negative anti-HEV IgM
serology in the control group.
Each patient with HEV-related ACLF was matched to three
patients with severe alcoholic hepatitis, based on the fol-
lowing criteria on admission: sex, age ± 10 years, total
bilirubin ± 350 μmol/l, international normalised ratio
(INR) ± 1.0, serum creatinine ± 130 μmol/l and MELD
(Model for End-stage Liver Disease) score ± 7 points. The
choice of these matching criteria was based on main clin-
ical aspects and validated prognostic factors commonly
used to assess these patients.
This study was approved by the Ethics Committee of the
Canton de Vaud (protocol no. 478/15).
Clinical definitions
HEV infection was defined by the presence of HEV RNA
in plasma. HEV-related death was defined by acute HEV
infection documented as a cause of death in the clinical
medical records and/or death certificate. ACLF was de-
fined according to European Association for the Study
of the Liver Chronic Liver Failure (EASL-CLIF) Consor-
tium, i.e., the failure of one of the six major organ systems
(liver, kidney, brain, coagulation, circulation and respira-
tion) assessed using the CLIF-C Organ Failure Scale [3,
13].
Quantitative PCR and genotyping
Quantitative PCR and HEV genotyping were performed as
described previously [8].
Histopathological evaluation of liver biopsies
All liver specimens were processed according to standard
histological methods, as described previously [11].
Statistical analysis
Continuous variables were reported as median (range) and
categorical variables as frequency (percentage). Aspartate
aminotransferase (AST) levels were compared between pa-
tients with HEV-related ACLF and controls with severe al-
coholic hepatitis using the Mann-Whitney U-test. The sta-
tistical analysis was performed using NCSS 2011 software.
A two-tailed p value <0.05 was considered significant.
Results
Five adult patients with HEV-related ACLF and death were
identified. Demographic, clinical and laboratory features,
as well as liver biopsy findings, are summarised in table
1. All patients had preexisting cirrhosis due to alcoholic or
nonalcoholic steatohepatitis and had not travelled in the 2
months preceding admission. HEV infection was molecu-
larly confirmed in all cases and likely acquired in Switzer-
land.
Clinical and laboratory presentation
Three patients (60%) were male; the median age was 66
years (range 51–76 years). Four patients were active
drinkers and one had insulin-dependent type 2 diabetes
mellitus. All patients presented with markedly increased
transaminases, with median alanine aminotransferase
(ALT) values of 2610 U/l (range 705–3134) and AST val-
ues of 2818 U/l (range 1176–8611). Liver function was
heavily altered on presentation, with a median total biliru-
bin of 414 μmol/l (range 293–606) and an INR of 2.5
(range 1.3–2.6). All patients developed ascites and hepatic
encephalopathy.
Histology
Transjugular liver biopsy was obtained in all patients with-
in a median time from presentation of 9 days (range 5–23).
Histological analyses were performed by expert liver
pathologists, with central reassessment by three indepen-
dent expert liver pathologists, as detailed in Lenggenhager
et al. [11]. Importantly, histological analyses revealed in all
cases a lesional pattern of florid steatohepatitis suggestive
of alcoholic or nonalcoholic origin on a background of cir-
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rhosis, and no inflammatory pattern readily pointing to vi-
ral hepatitis (fig. 1).
Virological analysis
Median HEV RNA was 4.0 log10 IU/ml (range 3.3–6.6).
HEV genotyping was successful in four patients, revealing
infection with genotype 3. Subtyping was successful in
three patients, revealing subtype 3h (formerly provisional-
ly designated as 3s), the dominant subtype circulating in
Switzerland [14–16]. Anti-HEV IgM was positive in all
patients.
Table 1: Clinical characteristics and laboratory features of patients with HEV-related ACLF and death.
Patient 1 2 3 4 5
Age (years) 76 74 66 59 51
Sex M M F M F
HEV RNA (log10 IU/ml) 3.3 3.9 4.7 6.6 4.0
HEV genotype 3h/s NA 3 3h/s 3h/s
Anti-HEV IgM + + + + +
ALT (U/l) at presentation 2610 705 3134 3054 1146
AST (U/l) at presentation 2818 1176 3126 8611 2358
TB (µmol/l) at presentation 606 293 414 364 512
INR at presentation 2.6 1.3 2.5 2.6 2.3
MELD at presentation 34 27 29 29 40
Ascites + + + + (SBP) + (SBP)
Hepatic encephalopathy + + + + +
Histology Steatohepatitis, cirrhosis Steatohepatitis, cirrhosis Steatohepatitis, cirrhosis Steatohepatitis, cirrhosis Steatohepatitis, cirrhosis
Cause of cirrhosis Alcohol Alcohol Alcohol NASHa Alcohol
Ribavirin treatment (d) 5 10 8 – 17
Time from hospitalisation to
death (d)
17 25 15 6 21
ACLF = acute-on-chronic liver failure; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HEV = hepatitis E virus; INR = international normalised ratio; MELD =
model for end-stage liver disease; NA = not available; NASH = nonalcoholic steatohepatitis; SBP = spontaneous bacterial peritonitis; TB = total bilirubin * Diagnosis of NASH was
based on alcohol consumption <30 g/day for men and <20 g/day for women. Patient 3 had insulin-dependent diabetes mellitus. The histological features of the five patients are
described in detail in Lenggenhager D, et al. [11]. Patients 1 and 2 had been included in a study on the demographics of acute hepatitis E acquired in Switzerland (Fraga M, et al.
[8]).
Figure 1: Histopathological findings in liver biopsies, exemplified by patient 3. (A) Cirrhotic liver parenchyma with steatosis (Masson trichrome
stain; scale bar: 500 μm). (B) Macro- and microvesicular steatosis with necroinflammation (H and E stain; scale bar: 100 μm). (C) Hepatocytes
with ballooning and Mallory-Denk hyaline (black arrowheads) (H and E stain; scale bar: 50 μm).
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Management and outcome
Based on histopathology, alcoholic hepatitis was initially
suspected in patients 1 and 2, prompting the introduction of
corticosteroid treatment. Ribavirin was started in four pa-
tients once HEV infection was diagnosed. Median duration
of ribavirin treatment was 9 days (range 5–17) and the me-
dian dose 200 mg per day (range 200–800). Median time
from hospitalisation to death was 17 days (range 6–25).
Case-control study
The five patients with HEV-related ACLF were matched
to 15 patients with histologically confirmed severe alco-
holic hepatitis on a background of cirrhosis, following the
matching criteria specified in the “Patients and Methods”
section. All patients in the control group were treated with
corticosteroids. Mortality among the matched patients was
high; 12 of the 15 patients (80%) died within 1 year of fol-
low-up. Importantly, AST levels in patients with HEV-re-
lated ACLF were significantly higher as compared to the
matched patients with severe alcoholic hepatitis (median
2818 U/l, range 1176–8611 vs 135 U/l, range 60–232; p =
0.002) (fig. 2).
Discussion
This retrospective, multicentre Swiss study emphasises
that histology can be misleading in cirrhotic patients with
acute HEV infection. However, high transaminase levels
may provide a clue to the diagnosis of acute HEV infection
in this context.
As demonstrated in our five patients and as elaborated in
Lenggenhager et al. [11], histological analyses did not sug-
gest viral hepatitis but oriented towards steatohepatitis in a
plausible context, thereby delaying the diagnosis of acute
hepatitis E. However, patients presented with markedly el-
evated transaminases, which pointed toward a possible su-
perimposed viral infection. Indeed, transaminases are clas-
sically only moderately elevated in the setting of alcoholic
hepatitis.
After matching our patients with HEV-related ACLF to pa-
tients with severe alcoholic hepatitis and a similarly poor
prognosis, we found that AST levels were significantly
Figure 2: Comparison of aspartate aminotransferase (AST) levels
at presentation between the five patients with hepatitis E virus
(HEV)-related acute-on-chronic liver failure and 15 matched pa-
tients with severe alcoholic hepatitis. The horizontal line within
each plot represents the median and the circles/squares represent
the AST levels at presentation for each patient. Statistical analysis
was performed using the Mann-Whitney U-test.
higher in patients with HEV-related ACLF. This finding
underscores the clinical relevance of marked transaminase
elevation in HEV-related ACLF.
Importantly, we cannot exclude the possibility that some
patients with HEV-triggered decompensation of liver cir-
rhosis may also have normal or only mildly elevated
transaminases, as recently shown by Blasco-Perrin et al.
[7] in a cohort of 11 patients with decompensation of cir-
rhosis triggered by acute HEV infection.
Although it was pointed out earlier that high levels of
transaminases in a patient with ACLF should prompt test-
ing for HEV infection [4], and notwithstanding the fact
that, according to European Association for the Study of
the Liver Clinical Practice Guidelines, HEV testing should
be performed in all patients with decompensation of chron-
ic liver disease independently from transaminase levels
[3], the present study shows that HEV infection underlying
ACLF may still be missed. Awareness of hepatitis E, espe-
cially in a context of ACLF, could still be improved, and
our observations may provide additional insight into a clin-
ical constellation where one should be especially attentive.
Rudler et al. investigated anti-HEV seroprevalence in a co-
hort of patients with histologically proven severe alcoholic
hepatitis. In this study, 6.5% of the patients presented posi-
tive anti-HEV IgM and IgG, but these markers of acute he-
patitis E were not associated with increased mortality [17].
However, no PCR data were available, and the variable
sensitivity and specificity of currently available serological
assays for hepatitis E may explain the difference from our
findings.
Two of the five patients were treated with corticosteroids
for presumed severe alcoholic hepatitis. A potential delete-
rious impact of corticosteroids on the clinical course can-
not be excluded, as they may not aggravate HEV infection
per se, but increase the risk of bacterial or fungal infection
in these fragile patients. The benefit of ribavirin in patients
with severe acute hepatitis E and HEV-related ACLF re-
mains uncertain [3]. Four of the five patients in the present
study were treated with ribavirin. However, antiviral treat-
ment was initiated late in the course of the disease, at a
stage of liver failure. Future studies will have to investi-
gate whether earlier diagnosis of HEV infection and an-
tiviral treatment in this setting may improve outcomes. On
a practical level, patients with cirrhosis should be advised
against the consumption of raw or undercooked pork or
game meat.
Our study presents some limitations. First, the sample size
is small. Second, the retrospective study design has inher-
ent limitations. Third, HEV infection in the control group
was ruled out only by negative anti-HEV IgM but not by
PCR. However, this is one of the few studies bringing to-
gether and describing in detail the clinical, laboratory and
histopathological features of patients with PCR-proven
HEV-related ACLF and death.
In conclusion, increased awareness is key to early diag-
nosis and management of acute HEV infection. While
histopathology may be misleading, high transaminases in
a setting of acute decompensation of cirrhosis may point
to HEV infection, which should be systematically sought
by molecular assays in case of cirrhosis decompensation
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and ACLF. Early identification of HEV infection is key to
avoid therapeutic delay in this setting.
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